Eating more plants has long been championed as a cornerstone of overall health, linked to everything from a stronger immune system to a healthier heart. Yet, despite decades of nutritional research, scientists are still unearthing the complex biochemical reasons why plant-based diets exert such a profound influence on the human body. New research suggests that dietary fiber, while undeniably crucial, tells only part of the story.
A pair of recent studies indicates that certain plant proteins capable of resisting digestion may play a surprisingly critical role in shaping the ecosystem of the gut. These proteins help determine whether intestinal bacteria churn out health-promoting compounds or potentially harmful ones. Furthermore, a companion study has turned a long-held scientific belief on its head, demonstrating that many of the chemical compounds previously thought to be manufactured exclusively by gut microbes can actually be produced by the human body’s own cells.
Plant-based diets are widely known to support digestive health, immune function, metabolism, and cardiovascular health. One major reason for this is their ability to maintain a diverse and thriving community of microorganisms residing in the intestines, collectively referred to as the gut microbiome. Many of these resident bacteria act as vital metabolic partners, helping break down food components that the human digestive system is inherently unequipped to process on its own.
While dietary fiber has traditionally taken center stage for providing essential nourishment to these microbes, plants also contain a wealth of phytochemicals. These natural substances give fruits and vegetables their vibrant, eye-catching colors and serve as protective mechanisms against environmental threats. When consumed, these compounds also contribute to human health. However, researchers are only now beginning to untangle the intricate chemical interactions that occur when trillions of gut bacteria go to work on digested plant foods.
Two pivotal studies spearheaded by Jenna AbuSalim and Joshua Rabinowitz—director of the Princeton Branch of the Ludwig Institute for Cancer Research—have shed fresh light on these processes. One study, published in the Proceedings of the National Academy of Sciences (PNAS), details how plant fiber and specialized proteins influence gut bacteria, steering them toward the production of beneficial chemical compounds rather than harmful byproducts. The second study, published in Nature Metabolism, challenges the longstanding assumption that many critical chemical substances circulating through the human body originate exclusively from intestinal microbes.
"There’s growing interest across medical disciplines in manipulating the human microbiome or using its metabolic products themselves for therapy," said Rabinowitz, reflecting on the broader clinical implications of the work. "Diet holds great promise for controlling the microbiome and its outputs. But to devise effective therapeutic interventions, we need to understand what aspects of the diet control which microbial outputs."
How Plant Foods Change the Chemicals Your Gut Produces
In the PNAS study, the research team trained their focus on a specific category of substances known as phenol metabolites. Metabolites are the chemical products formed when the body or resident microorganisms break down, process, and metabolize nutrients. Some of these chemical agents are essential for normal biological functions, while others can accumulate and contribute significantly to various health problems.
The phenol metabolites investigated by the team are generated when gut bacteria process two specific amino acids: tyrosine and phenylalanine. Although amino acids serve as the fundamental building blocks of proteins, the metabolic compounds they ultimately yield can have vastly contrasting effects on human health.
For instance, two distinct metabolites derived from phenylalanine—phenylpropionate and hippuric acid—are strongly associated with a healthy body weight and superior gut health. Conversely, two compounds derived from tyrosine, known as p-cresol sulfate and phenol sulfate, have been linked directly to worse clinical outcomes in cancer patients, alongside widespread harmful effects throughout the body in individuals suffering from chronic kidney disease.
Keen to understand what drives these divergent pathways, the researchers wanted to discover whether different components of everyday plant foods could directly influence which of these substances gut microbes choose to manufacture.
"Our studies showed that both the fiber and indigestible proteins from plants—which we call ‘proteins imitating fiber,’ or Prif—shift the balance of phenol metabolites from the harmful kind made from tyrosine to the healthful variety derived from phenylalanine," explained AbuSalim.
An Overlooked Plant Protein Works Alongside Fiber
While the health benefits of dietary fiber have been exhaustively studied and widely publicized for decades, scientists have historically paid far less attention to the plant proteins that manage to pass through the human digestive system without being fully broken down or absorbed.
The researchers discovered that these indigestible proteins, termed Prifs, successfully reach the gut microbiome intact, where they subsequently serve as rich raw material for bacterial metabolism. By entering the microbial food web, they actively influence which bacterial species thrive and which chemical compounds are ultimately synthesized.
Crucially, these specialized proteins do not operate in a vacuum. Instead, they cooperate dynamically with plant fiber to alter how gut bacteria process incoming nutrients, effectively shifting microbial activity away from detrimental pathways and toward the synthesis of beneficial phenol metabolites.
This breakthrough discovery suggests that the nutritional value of plant-based foods may depend on much more than their familiar, well-documented concentrations of fiber, vitamins, and minerals. The precise amount and chemical type of protein that escapes human digestion could play an equally vital role in determining how a specific food shapes the gut microbiome.
When Gut Bacteria Run Low on Fiber, They May Feed on Your Gut’s Protective Mucus
One of the most striking and clinically concerning findings of the research centers on where gut bacteria actually obtain the raw materials needed to produce harmful metabolites when dietary inputs are lacking.
To investigate this phenomenon, the research team labeled proteins using stable, non-radioactive isotopes. This advanced scientific technique acts as a subtle chemical signature, allowing investigators to track with pinpoint accuracy where proteins travel and how they are processed within the digestive systems of mice.
The experiments revealed a stark and important difference between the biological origins of beneficial versus harmful phenols. The potentially harmful phenols were traced back to gut bacteria breaking down proteins belonging directly to the host organism—specifically, the proteins found within the thick, protective mucus layer that coats the intestinal walls. This crucial mucus layer serves as a physical barrier separating intestinal microbes from the delicate epithelial cells lining the gut, forming a foundational component of the body’s natural innate defenses.
Meanwhile, the health-promoting beneficial phenols were found to be produced almost entirely from the indigestible proteins supplied externally by food.
Dietary fiber played a protective role by suppressing the bacterial breakdown of the gut’s vulnerable mucosal lining, thereby curbing the production of harmful phenols. Simultaneously, the indigestible plant proteins, or Prifs, supplied an alternative, abundant source of dietary protein for the gut bacteria, actively encouraging them to manufacture beneficial compounds instead.
Together, these findings unveil two complementary mechanisms through which plant foods shape intestinal chemistry. Fiber discourages hungry bacteria from consuming proteins within the gut’s protective mucus, while Prifs provide an alternative nutritional bounty that supports the production of healthier metabolites.
"We think Prifs represent an emerging class of dietary nutrients that shape the composition of the gut microbiome and could have a far-reaching influence on metabolic health," said AbuSalim. The profound implications of this discovery could eventually extend far beyond academic journals, potentially reshaping nutrition labels and public health dietary guidelines.
"Food packaging may eventually list Prif right below fiber," Rabinowitz suggested.
A Second Discovery Challenges What Scientists Thought About Gut Bacteria
While the PNAS paper explored dietary proteins, the companion study published in Nature Metabolism tackled an entirely different, yet equally foundational, question: Are gut bacteria truly responsible for producing all of the metabolic compounds traditionally attributed to them?
Alongside phenol metabolites, the research team examined indole metabolites, which are formed from the processing of tryptophan, another essential amino acid abundant in dietary proteins. These substances have generated immense scientific interest because they participate directly in biological processes tied to inflammation, immune activity, and chronic disease. Researchers have heavily investigated their involvement in inflammatory bowel disease, neurodegenerative disorders, and cancer, noting that certain indole metabolites can even influence the spread of cancer and the immune system’s capacity to recognize and attack tumors.
For years, the scientific community has largely assumed that gut bacteria are the exclusive source of these compounds. That long-standing belief has heavily driven the development of targeted probiotics, prebiotics, and dietary interventions designed to boost the production of potentially beneficial indole metabolites.
However, this entire therapeutic approach relies on a massive underlying assumption: that intestinal microbes are genuinely responsible for producing most, or even all, of the compounds researchers are trying to manipulate. If mammalian cells themselves happen to manufacture substantial amounts of these same metabolites, then modifying the microbiome alone may prove to be an ineffective way to control their circulating levels.
Your Body Can Make Compounds Once Attributed to Gut Microbes
To test this hypothesis, the research team utilized sophisticated isotope tracing techniques across mice, rats, and human cell cultures to track precisely how different metabolites were synthesized within a living system.
The results thoroughly challenged conventional medical thinking. Mammalian cells proved fully capable of generating numerous phenol and indole metabolites entirely independently of any intestinal bacteria.
Among these endogenously produced compounds were indole-3-lactate and indole-3-acetate, two biologically significant molecules that had long been universally considered exclusive products of microbial metabolism.
To gather further proof, the researchers observed what happened when antibiotics disrupted the natural intestinal microbiome. If certain metabolites depended entirely on the presence of gut bacteria, their concentrations in the body would logically be expected to plummet sharply once those bacterial populations were depleted.
Yet, contrary to expectations, many metabolites remained present at substantial levels in the blood of antibiotic-treated mice. A remarkably similar pattern emerged in clinical samples gathered from human patients receiving antibiotics, including individuals undergoing active cancer treatment.
Other compounds, however, behaved differently. Levels of indole-3-propionate and p-cresol sulfate—which are indeed produced exclusively by microbes—dropped precipitously following antibiotic treatment. These contrasting results provided definitive evidence that while some metabolites are strictly dependent on intestinal bacteria, others can also be manufactured autonomously by the body’s own internal metabolic machinery.
This fundamental distinction matters immensely, as it threatens to fundamentally alter how researchers design and develop future pharmaceutical and nutritional treatments intended to elevate beneficial metabolites or suppress harmful ones.
What These Discoveries Mean for Nutrition and Future Treatments
Taken together, these two groundbreaking studies offer a vastly more detailed and nuanced understanding of how diet, gut microbes, and human physiology interact.
The first study identifies an overlooked category of plant proteins that works in tandem with fiber to directly influence bacterial activity, helping tip the biological balance away from harmful metabolic products. The second study demonstrates that the human body itself possesses the hidden capability to produce many of the compounds once believed to originate exclusively from gut bacteria.
Both findings hold profound implications for ongoing research into metabolic disease, digestive health, oncology, and a wide array of other conditions influenced by the microbiome. Furthermore, they suggest that future attempts to manipulate human gut chemistry through targeted diets, probiotics, or advanced medical therapies will need to account for both microbial activity and the body’s own robust metabolic capabilities.
Because much of the current experimental evidence derives from animal models and laboratory cell studies, additional clinical research will be required to determine precisely how these newly discovered mechanisms influence long-term health outcomes in humans.
Nevertheless, achieving a sharper understanding of how different food components interact with both the microbiome and human metabolism could eventually make dietary advice far more precise, while helping biomedical researchers identify entirely novel therapeutic strategies.
"Beyond that," Rabinowitz concluded, "a clearer picture of how different foods interact with the microbiome to modulate the production of bacterial metabolites will help sharpen the guidance nutritionists and doctors can give to people for disease prevention and therapy."
These studies were generously funded by the Ludwig Institute for Cancer Research, the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases, the Princeton Alliance for Collaborative Research and Innovation, and Princeton University.
Aside from his post as Director of the Princeton Branch of the Ludwig Institute for Cancer Research, Joshua Rabinowitz serves as a professor in the Department of Chemistry & Lewis-Sigler Institute for Integrative Genomics and is a member of the Rutgers Cancer Institute.
